Moss 28 March, 2025
Gentian Diagnostics ASA, a fast growing developer and manufacturer of diagnostic tests, is excited to announce two strategic appointments that will enhance its commercial capabilities and support long-term growth.
Markus Jaquemar, previously the CCO of Gentian, has been appointed as Chief Growth Officer, effective March 2025. In this new role, Markus will focus on business development, shaping Gentian’s long-term strategy, and leading growth initiatives, including exploring new partnerships, technologies, and market expansions. With over 30 years of experience in life science and diagnostics commercialization and marketing, Markus brings a wealth of expertise to the position. Prior to joining Gentian in 2020, he held various marketing, sales, and business management roles at Beckman Coulter, Agilent Technologies, and Becton Dickinson.
Additionally, we are pleased to welcome Hanne Kjellevold Kristiansen as Vice President, Commercial. Hanne joins Gentian from Siemens Healthineers, where she held several positions of increasing responsibility in both Norway and the USA, most recently serving as Country Sales Lead for Siemens Healthineers diagnostics division in Norway. With over 20 years of industry experience, Hanne has also worked for companies such as Axis-Shield, GE Healthcare, and Dade Behring. She holds degrees in Biomedical Engineering and Business Administration. Hanne’s extensive experience and skills will be instrumental in supporting Gentian’s ambitions for double-digit profitable growth, particularly in the US market. She will also lead the commercial team in preparation for the anticipated 2026 launch of Gentian’s late-stage pipeline asset, the first-in-class NT-proBNP heart failure marker on clinical chemistry platforms.
These appointments underscore Gentian’s commitment to driving innovation and expanding its market presence globally.
About Gentian Diagnostics Gentian Diagnostics (OSE: GENT), develops and manufactures high-quality, in vitro diagnostic reagents. Our mission is to innovate diagnostic efficiency for better treatment decisions. Gentian’s expertise and focus lies within immunoassays, specifically for infections, inflammation, kidney disease and congestive heart failure. By converting existing and clinically relevant biomarkers to the most efficient, high-throughput analysers, the company contributes to saving costs and protecting life. Gentian Diagnostics is headquartered in Moss, Norway, serving the global human and veterinary diagnostics markets through sales and representative offices in Sweden, USA, and China. For more information, please visit www.gentian.com.
IR contact:
Njaal Kind, CFO
+47 919 06 525 (mobile)